See more : Mineral Resources Limited (MALRY) Income Statement Analysis – Financial Results
Complete financial analysis of Codex DNA, Inc. (DNAY) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Codex DNA, Inc., a leading company in the Medical – Devices industry within the Healthcare sector.
- Tethys Petroleum Limited (TPL.V) Income Statement Analysis – Financial Results
- Asahi India Glass Limited (ASAHIINDIA.BO) Income Statement Analysis – Financial Results
- Solar Park Initiatives, Inc. (SOPV) Income Statement Analysis – Financial Results
- Neurones S.A. (0GX2.L) Income Statement Analysis – Financial Results
- Centrum Capital Limited (CENTRUM.BO) Income Statement Analysis – Financial Results
Codex DNA, Inc. (DNAY)
About Codex DNA, Inc.
Codex DNA, Inc., a synthetic biology company, manufactures and sells synthetic biology instruments, reagents, and associated products and related services, primarily to pharmaceutical and academic laboratories worldwide. Its solutions include BioXp system that empowers researchers to go from a digital DNA sequence to endpoint-ready synthetic DNA; BioXp portal, an online portal that offers an intuitive guided workflow and design tools for building new DNA sequences and assembling them into vectors of choice; BioXp kits that contain building blocks and reagents, including its Gibson Assembly branded reagents, for specific synthetic biology workflow applications; Cloud-based scripts; Benchtop reagents that contain all the reagents necessary to proceed with a specific synthetic biology workflow on the benchtop using products generated on the BioXp system; Biofoundry Services, which enable a customer to order and receive the BioXp system endpoint-ready products, such as genes, clones, cell-free amplified DNA, and variant libraries; and short oligo ligation assembly enzymatic DNA synthesis. It also serves government institutions, contract research organizations, and synthetic biology companies. The company was formerly known as SGI-DNA, Inc. and changed its name to Codex DNA, Inc. in March 2020. Codex DNA, Inc. was incorporated in 2011 and is headquartered in San Diego, California.
| Metric | 2022 | 2021 | 2020 |
|---|---|---|---|
| Revenue | 27.44M | 11.04M | 6.58M |
| Cost of Revenue | 11.84M | 6.74M | 2.95M |
| Gross Profit | 15.60M | 4.30M | 3.63M |
| Gross Profit Ratio | 56.84% | 38.93% | 55.12% |
| Research & Development | 23.46M | 14.55M | 8.93M |
| General & Administrative | 22.13M | 14.23M | 4.13M |
| Selling & Marketing | 16.49M | 10.90M | 6.93M |
| SG&A | 38.62M | 25.13M | 11.06M |
| Other Expenses | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 62.08M | 39.67M | 19.99M |
| Cost & Expenses | 73.92M | 46.42M | 22.94M |
| Interest Income | 0.00 | 0.00 | 0.00 |
| Interest Expense | -1.22M | -1.37M | 690.00K |
| Depreciation & Amortization | 3.23M | 908.00K | 1.46M |
| EBITDA | -46.49M | -39.41M | -15.86M |
| EBITDA Ratio | -169.44% | -356.83% | -241.15% |
| Operating Income | -49.71M | -40.31M | -16.36M |
| Operating Income Ratio | -181.20% | -365.05% | -248.80% |
| Total Other Income/Expenses | -1.96M | -3.57M | -1.64M |
| Income Before Tax | -48.45M | -38.94M | -18.01M |
| Income Before Tax Ratio | -176.59% | -352.66% | -273.80% |
| Income Tax Expense | -24.00K | 14.00K | 5.00K |
| Net Income | -48.42M | -38.96M | -18.01M |
| Net Income Ratio | -176.50% | -352.78% | -273.87% |
| EPS | -1.64 | -1.83 | -0.84 |
| EPS Diluted | -1.64 | -1.83 | -0.84 |
| Weighted Avg Shares Out | 29.46M | 21.32M | 21.32M |
| Weighted Avg Shares Out (Dil) | 29.46M | 21.32M | 21.32M |
Telesis Bio, Inc. (DNAY) Q3 2022 Earnings Call Transcript
Codex DNA (DNAY) Reports Q3 Loss, Tops Revenue Estimates
Telesis Bio to Report Third Quarter 2022 Financial Results and Provide a Corporate Update on November 8
Codex DNA (DNAY) Could Find Support Soon, Here's Why You Should Buy the Stock Now
Codex DNA, Inc. (DNAY) CEO Todd Nelson on Q2 2022 Results - Earnings Call Transcript
Codex DNA (DNAY) Reports Q2 Loss, Tops Revenue Estimates
Codex DNA to Report Second Quarter 2022 Financial Results on Tuesday, August 9, 2022
Codex DNA to Present at the 2022 Jefferies Healthcare Conference
Codex DNA, Inc. (DNAY) CEO Todd Nelson on Q1 2022 Results - Earnings Call Transcript
Codex DNA to Report First Quarter 2022 Financial Results on Tuesday, May 10, 2022
Source: https://incomestatements.info
Category: Stock Reports